MedTrace Logo

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

NCT06547203 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-08-09

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal cancer.

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Cetuximab

Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks

DRUG

Toripalimab

Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.

DRUG

Irinotecan

Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-18
Primary Completion
2026-07-30
Completion
2029-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547203 on ClinicalTrials.gov